Abstract
The diagnosis and assessment of brain damage is currently based on the clinical examination and the modern neuro-imaging techniques. Electrophysiology, haemodynamic monitoring and invasive neuromonitoring constitute additional tools for monitoring of the brain function and clinical course of the patient. However, despite the substantial progress, clinical and neuro-monitoring methods are quite often not sufficient to evaluate and quantify the severity of the initial and secondary destructive processes and hence they cannot guide efficient therapeutic measures and prognosticate effectively the outcome. During the last decades, researchers and clinicians have focused on specific markers of brain cell damage to improve the diagnosis and monitoring of neurological insults. Lactate dehydrogenase, creatine kinase, neuron specific enolase, have been proposed as potential markers of brain injury. More recently, other glial markers such as the Myelin Basic Protein, the glial fibrillary acidic protein and the S-100B protein have been measured in blood and used as surrogate biochemical markers for brain injury. This review summarizes published findings on the above brain specific serum biochemical markers with emphasis on those with clinical utility.
Keywords: Brain injury, neurotrauma, stroke, ischaemia, subarachnoid haemorrhage, tbi, brain tumours, brain biochemical markers
Mini-Reviews in Medicinal Chemistry
Title: Serum Biochemical Markers of Brain Injury
Volume: 9 Issue: 2
Author(s): S. Korfias, A. Papadimitriou, G. Stranjalis, C. Bakoula, G. Daskalakis, A. Antsaklis and D. E. Sakas
Affiliation:
Keywords: Brain injury, neurotrauma, stroke, ischaemia, subarachnoid haemorrhage, tbi, brain tumours, brain biochemical markers
Abstract: The diagnosis and assessment of brain damage is currently based on the clinical examination and the modern neuro-imaging techniques. Electrophysiology, haemodynamic monitoring and invasive neuromonitoring constitute additional tools for monitoring of the brain function and clinical course of the patient. However, despite the substantial progress, clinical and neuro-monitoring methods are quite often not sufficient to evaluate and quantify the severity of the initial and secondary destructive processes and hence they cannot guide efficient therapeutic measures and prognosticate effectively the outcome. During the last decades, researchers and clinicians have focused on specific markers of brain cell damage to improve the diagnosis and monitoring of neurological insults. Lactate dehydrogenase, creatine kinase, neuron specific enolase, have been proposed as potential markers of brain injury. More recently, other glial markers such as the Myelin Basic Protein, the glial fibrillary acidic protein and the S-100B protein have been measured in blood and used as surrogate biochemical markers for brain injury. This review summarizes published findings on the above brain specific serum biochemical markers with emphasis on those with clinical utility.
Export Options
About this article
Cite this article as:
Korfias S., Papadimitriou A., Stranjalis G., Bakoula C., Daskalakis G., Antsaklis A. and Sakas E. D., Serum Biochemical Markers of Brain Injury, Mini-Reviews in Medicinal Chemistry 2009; 9 (2) . https://dx.doi.org/10.2174/138955709787315994
DOI https://dx.doi.org/10.2174/138955709787315994 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents
Medicinal Chemistry PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology MicroRNAs: Key Players in Microglia and Astrocyte Mediated Inflammation in CNS Pathologies
Current Medicinal Chemistry Protein S-100B - A Prognostic Marker for Cerebral Damage
Current Medicinal Chemistry Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research DHA: An Excellent Source of Bioactive Heterocycles
Letters in Organic Chemistry The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central Nervous System Pathological Conditions
Current Neuropharmacology The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design Berberine Ameliorates Cognitive Impairment by Regulating Microglial Polarization and Increasing Expression of Anti-inflammatory Factors following Permanent Bilateral Common Carotid Artery Occlusion in Rats
CNS & Neurological Disorders - Drug Targets Ocular Drug Delivery - New Strategies for Targeting Anterior and Posterior Segments of the Eye
Current Pharmaceutical Design Optimal Sedation for the Ventilation of Critically Ill Patients
Current Respiratory Medicine Reviews The Role of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke: From Laboratory to Clinics
Current Vascular Pharmacology MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Anesthesia, Calcium Homeostasis and Alzheimers Disease
Current Alzheimer Research Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders
Current Alzheimer Research Repurposing Pharmaceuticals as Neuroprotective Agents for Cerebral Malaria
Current Clinical Pharmacology Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry